LAIV Inducing Cross Protection
LAIV 诱导交叉保护
基本信息
- 批准号:8951382
- 负责人:
- 金额:$ 18.76万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2015
- 资助国家:美国
- 起止时间:2015-05-01 至 2017-04-30
- 项目状态:已结题
- 来源:
- 关键词:2 year oldAdultAnimal ModelAntibodiesAntibody ResponseAttenuatedAttenuated VaccinesChildDevelopmentEpidemicEpitopesFerretsFigs - dietaryGenesGoalsHeadHemagglutininHumanImmune responseImmunityInactivated VaccinesInfluenzaInfluenza A Virus, H1N1 SubtypeInfluenza A Virus, H5N1 SubtypeInfluenza A virusInfluenza vaccinationLicensingLifeM2 proteinMusMutationPhenotypePolymeraseProteinsPublic HealthRecombinantsSafetySiteSupplementationTandem Repeat SequencesTestingVaccinatedVaccinesVariantVertebral columnVirusattenuationbaseimmunogenicimmunogenicityimprovedinfluenza virus vaccineinfluenzavirusmutantnovelnovel strategiespandemic diseaseprotective efficacypublic health relevancerecombinant virusvaccine trialvector vaccine
项目摘要
DESCRIPTION (provided by applicant): Live attenuated influenza vaccine (LAIV) is a safe and effective platform for human use, and shown to have higher efficacy in children than inactivated vaccine. Nonetheless, current influenza vaccines including LAIV do not provide cross-protection against antigenically distinct epidemic strains or the unanticipated emergence of new pandemic strains. It is of a high priority to improve the breadth of cross protective efficacy of strain-specific vaccines based on hemagglutinin (HA) immunity. Our preliminary studies demonstrated that immune responses to highly conserved influenza M2 protein (M2e) provided a broader range of cross-protection (H1, H3, and H5 subtypes). In addition, we recently generated novel influenza mutants that express a chimeric conserved M2e-HA, which showed attenuated phenotypes as well as provided significantly broad and enhanced cross-protection. These findings strongly suggest that it should be possible to produce highly cross protective and safe LAIV. Thus, it is highly expected that incorporating conserved-protective M2e into HA will overcome the strain-specific protection of HA as well as poor immunogenicity of M2. The central hypothesis is that recombinant LAIV containing M2e-HA will be safer and more effective in inducing a broader range of cross-protection. The first goal (aim 1) is to generate recombinant LAIV containing M2e-HA and to determine the safety and cross-protective efficacy of recombinant LAIV. The aim 2 will test recombinant LAIV-M2e vaccines in ferrets, which is a more relevant animal model for testing influenza vaccines.
描述(由申请人提供):减毒活疫苗(LAIV)是一个安全有效的人类使用平台,并被证明在儿童中具有比灭活疫苗更高的效力。尽管如此,目前的流感疫苗,包括LAIV,并没有针对抗原性不同的流行毒株或意外出现的新大流行毒株提供交叉保护。提高基于血凝素(HA)免疫的毒株特异性疫苗的交叉保护效果的广度是当务之急。我们的初步研究表明,对高度保守的流感M2蛋白(M2e)的免疫反应提供了更广泛的交叉保护(H1、H3和H5亚型)。此外,我们最近产生了新的流感突变体,表达嵌合保守的M2e-HA,它表现出减弱的表型,并提供显著广泛和增强的交叉保护。这些发现有力地表明,产生高度交叉保护和安全的LAIV是可能的。因此,将保守的保护性M2e引入HA中将克服HA的毒株特异性保护以及M2的免疫原性差,因此人们对此寄予厚望。中心假设是含有M2e-HA的重组LAIV将更安全和更有效地诱导更广泛的交叉保护。第一个目标(目标1)是制备含有M2e-HA的重组LAIV,并确定重组LAIV的安全性和交叉保护效果。Aim 2将在雪貂身上测试重组LAIV-M2e疫苗,这是测试流感疫苗的更相关的动物模型。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(1)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
SANG-MOO KANG其他文献
SANG-MOO KANG的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('SANG-MOO KANG', 18)}}的其他基金
Seasonal and universal Vaccination in aged populations with pre-existing immunity
对已有免疫力的老年人群进行季节性和普遍的疫苗接种
- 批准号:
10408841 - 财政年份:2021
- 资助金额:
$ 18.76万 - 项目类别:
Seasonal and universal Vaccination in aged populations with pre-existing immunity
对已有免疫力的老年人群进行季节性和普遍的疫苗接种
- 批准号:
10313001 - 财政年份:2021
- 资助金额:
$ 18.76万 - 项目类别:
Seasonal and universal Vaccination in aged populations with pre-existing immunity
对已有免疫力的老年人群进行季节性和普遍的疫苗接种
- 批准号:
10613576 - 财政年份:2021
- 资助金额:
$ 18.76万 - 项目类别:
Universal epitopes-based recombinant influenza vaccines
基于通用表位的重组流感疫苗
- 批准号:
10092937 - 财政年份:2020
- 资助金额:
$ 18.76万 - 项目类别:
Universal epitopes-based recombinant influenza vaccines
基于通用表位的重组流感疫苗
- 批准号:
9979495 - 财政年份:2020
- 资助金额:
$ 18.76万 - 项目类别:
Influenza vaccines inducing broadly cross protective immunity
流感疫苗诱导广泛的交叉保护性免疫
- 批准号:
8416164 - 财政年份:2011
- 资助金额:
$ 18.76万 - 项目类别:
相似海外基金
Co-designing a lifestyle, stop-vaping intervention for ex-smoking, adult vapers (CLOVER study)
为戒烟的成年电子烟使用者共同设计生活方式、戒烟干预措施(CLOVER 研究)
- 批准号:
MR/Z503605/1 - 财政年份:2024
- 资助金额:
$ 18.76万 - 项目类别:
Research Grant
RAPID: Affective Mechanisms of Adjustment in Diverse Emerging Adult Student Communities Before, During, and Beyond the COVID-19 Pandemic
RAPID:COVID-19 大流行之前、期间和之后不同新兴成人学生社区的情感调整机制
- 批准号:
2402691 - 财政年份:2024
- 资助金额:
$ 18.76万 - 项目类别:
Standard Grant
Early Life Antecedents Predicting Adult Daily Affective Reactivity to Stress
早期生活经历预测成人对压力的日常情感反应
- 批准号:
2336167 - 财政年份:2024
- 资助金额:
$ 18.76万 - 项目类别:
Standard Grant
Elucidation of Adult Newt Cells Regulating the ZRS enhancer during Limb Regeneration
阐明成体蝾螈细胞在肢体再生过程中调节 ZRS 增强子
- 批准号:
24K12150 - 财政年份:2024
- 资助金额:
$ 18.76万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Migrant Youth and the Sociolegal Construction of Child and Adult Categories
流动青年与儿童和成人类别的社会法律建构
- 批准号:
2341428 - 财政年份:2024
- 资助金额:
$ 18.76万 - 项目类别:
Standard Grant
Understanding how platelets mediate new neuron formation in the adult brain
了解血小板如何介导成人大脑中新神经元的形成
- 批准号:
DE240100561 - 财政年份:2024
- 资助金额:
$ 18.76万 - 项目类别:
Discovery Early Career Researcher Award
Laboratory testing and development of a new adult ankle splint
新型成人踝关节夹板的实验室测试和开发
- 批准号:
10065645 - 财政年份:2023
- 资助金额:
$ 18.76万 - 项目类别:
Collaborative R&D
Usefulness of a question prompt sheet for onco-fertility in adolescent and young adult patients under 25 years old.
问题提示表对于 25 岁以下青少年和年轻成年患者的肿瘤生育力的有用性。
- 批准号:
23K09542 - 财政年份:2023
- 资助金额:
$ 18.76万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Identification of new specific molecules associated with right ventricular dysfunction in adult patients with congenital heart disease
鉴定与成年先天性心脏病患者右心室功能障碍相关的新特异性分子
- 批准号:
23K07552 - 财政年份:2023
- 资助金额:
$ 18.76万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Issue identifications and model developments in transitional care for patients with adult congenital heart disease.
成人先天性心脏病患者过渡护理的问题识别和模型开发。
- 批准号:
23K07559 - 财政年份:2023
- 资助金额:
$ 18.76万 - 项目类别:
Grant-in-Aid for Scientific Research (C)














{{item.name}}会员




